Khan Ashraful I, Chowdhury Fahima, Leung Daniel T, Larocque Regina C, Harris Jason B, Ryan Edward T, Calderwood Stephen B, Qadri Firdausi
Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh; Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA.
Int J Infect Dis. 2015 Oct;39:20-4. doi: 10.1016/j.ijid.2015.08.006. Epub 2015 Aug 14.
The objective of this study was to examine the clinical and immunological features of cholera in pregnancy.
Women of reproductive age presenting to the icddr,b Dhaka hospital with cholera, and enrolled as part of a larger cohort study, were tested for pregnancy on admission. We compared initial clinical features and immune responses of pregnant patients with non-pregnant female patients at days 2, 7 and 21 after infection.
Among reproductive age women enrolled between January 2001 and May 2006, 9.7% (14/144) were pregnant. The duration of diarrhoea prior to admission tended to be higher in pregnant compared to non-pregnant patients (p=0.08), but other clinical characteristics did not differ. Antibody responses to cholera toxin B subunit (CtxB), toxin-coregulated pilus A (TcpA), Vibrio cholerae lipopolysaccharide (LPS), and serum vibriocidal antibody responses, were comparable between pregnant and non-pregnant patients. There were no deaths among the pregnant cases or non-pregnant controls, and no adverse foetal outcomes, including stillbirths, during 21 days of follow up of pregnant cases.
To our knowledge, this is the first report of immune responses in pregnant women with cholera. We found that pregnant woman early in pregnancy has comparable clinical illness and subsequent immune responses compared to non-pregnant women. These findings suggest that the evaluation of safety and immunogenicity of oral cholera vaccines in pregnancy should be an area of future investigations.
本研究的目的是探讨妊娠期霍乱的临床和免疫学特征。
在达卡国际腹泻疾病研究中心医院就诊的患有霍乱的育龄妇女,作为一项更大队列研究的一部分被纳入,入院时进行妊娠检测。我们比较了感染后第2天、第7天和第21天孕妇与非孕妇患者的初始临床特征和免疫反应。
在2001年1月至2006年5月纳入的育龄妇女中,9.7%(14/144)为孕妇。与非孕妇相比,孕妇入院前腹泻持续时间往往更长(p = 0.08),但其他临床特征无差异。孕妇和非孕妇对霍乱毒素B亚单位(CtxB)、毒素调节菌毛A(TcpA)、霍乱弧菌脂多糖(LPS)的抗体反应以及血清杀菌抗体反应相当。孕妇病例和非孕妇对照均无死亡,孕妇病例随访21天期间无不良胎儿结局,包括死产。
据我们所知,这是关于妊娠期霍乱患者免疫反应的首份报告。我们发现,妊娠早期的孕妇与非孕妇相比,临床疾病及后续免疫反应相当。这些发现表明,评估口服霍乱疫苗在妊娠期的安全性和免疫原性应是未来研究的一个领域。